Cardiff Oncology reports 49% confirmed ORR with onvansertib+SoC in Phase 2 mCRC trial; Q2 cash $71M

Cardiff Oncology, Inc.

Confirmed ORR 49% (30mg onvansertib+SoC) vs 30% control in ITT population (N=110); early PFS trend favoring 30mg.
Onvansertib well-tolerated; neutropenia most common grade 3+ AE; no unexpected toxicities.
Q2 operating expenses $14.9M (vs $12.7M); cash and investments $71.0M; runway into Q1 2027.
Appointed Dr. Roger Sidhu as CMO; completed enrollment in 41-site CRDF-004 trial.
Company expects to provide update on first-line mCRC program by Q1 2026.

item 2.02item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.